June 19, 2022
Loading...
You are here:  Home  >  'Amgen'  -  Page 60
Latest

Amgen spinout Atara raises $38.5 million

By   /  Tuesday, December 17th, 2013  /  Health Care & Life Science, Technology, Top Stories  /  Comments Off on Amgen spinout Atara raises $38.5 million

Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.

Latest

Amgen profits leap in third quarter

By   /  Tuesday, October 22nd, 2013  /  Banking & Finance, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Amgen profits leap in third quarter

Shares of Thousand Oaks-based Amgen climbed past the $117 mark in after-hours trading Oct. 22 as third-quarter results blew through analyst forecasts with profits rising 24 percent. The world’s biggest biotech company reported a profit of $1.37 billion, or $1.79 per share, on revenue of $4.75 billion. Analysts were forecasting revenue of $4.6 billion and Read More →

Latest

Gov. Brown vetoes Amgen-backed anti-biosimilars bill

By   /  Friday, October 18th, 2013  /  Banking & Finance, Health Care & Life Science, Technology, Top Stories, Tourism, Tri-County Public Companies  /  Comments Off on Gov. Brown vetoes Amgen-backed anti-biosimilars bill

Gov. Jerry Brown vetoed a bill supported by Thousand Oaks-based Amgen and other biotechnology companies that would have made it more difficult for pharmacists to dispense so-called biosimilars, the biotech industry’s analogue to generic pharmaceuticals.

Senate Bill 598, approved by both houses of the legislature, looked mostly like a procedural change to state’s pharmacy laws. If it passed, the bill would have allowed pharmacists to fill prescriptions with biosimilars that the U.S. Food and Drug Administration deems “interchangeable” with brand-name counterparts.

Latest

Onyx buy sets dealmaking era for Amgen

By   /  Friday, August 30th, 2013  /  Banking & Finance, Technology, Top Stories  /  Comments Off on Onyx buy sets dealmaking era for Amgen

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

The top five financial truths in blockbuster Amgen-Onyx deal

By   /  Friday, August 30th, 2013  /  Columns, Opinion  /  Comments Off on The top five financial truths in blockbuster Amgen-Onyx deal

For sheer size and scale, Amgen’s $10.4 billion purchase of South San Francisco-based cancer drug maker Onyx Pharmaceuticals dwarfs any recent deal in the Tri-Counties. For size, let’s remember that Dole Food Co. is selling its entire self for about $1.3 billion and that Santa Barbara Bank & Trust parent Pacific Capital Bancorp, previously the Read More →

Latest

Questions surround insider trading probe around Amgen bid for Onyx

By   /  Friday, July 12th, 2013  /  Columns, Opinion  /  Comments Off on Questions surround insider trading probe around Amgen bid for Onyx

Less than a week after Onyx spurned Amgen’s takeover bid, the SEC went to court and froze some $4.3 million in accounts in the Canary Islands and Beirut.

Latest

Amgen news kicks off Q3 trading: CalAmp frontrunner in first-half standings

By   /  Friday, July 5th, 2013  /  Banking & Finance, Features, Personal Finance, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen news kicks off Q3 trading: CalAmp frontrunner in first-half standings

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.